Table 3.
Slopes from linear mixed model for estimated Glomerular Filtration Rate (eGFR) over the course of follow-up in African-American SPRINT participants by treatment group and APOL1 risk genotype
| Group | Time Perioda | Group |
APOL1 G1+G2=2 Slope (95% CI)b |
APOL1 G1+G2=0/1 Slope (95% CI)b |
APOL1 G1+G2: 2 - 0/1 Difference (95% CI) |
p-value |
|---|---|---|---|---|---|---|
| All | Acute (≤6M) |
Standard | −0.31 (−2.87, 2.26) | 0.80 (−0.46, 2.07) | −1.11 (−3.69, 1.47) | 0.398 |
| All | Acute (≤6M) |
Intensive | −4.18 (−6.57, −1.79) | −3.53 (−4.82, −2.25) | −0.65 (−3.06, 1.77) | 0.600 |
|
| ||||||
| All | Chronic (>6M) |
Standard | −1.13 (−2.34, 0.08) | −0.97 (−1.42, −0.52) | −0.16 (−1.45, 1.12) | 0.806 |
| All | Chronic (>6M) |
Intensive | −1.36 (−2.46, −0.26) | −1.01 (−1.47, −0.54) | −0.35 (−1.54, 0.84) | 0.564 |
|
| ||||||
| CKD (eGFR<60 ml/min/1.73m2) | Acute (≤6M) |
Standard | 0.85 (−2.22, 3.91) | 2.07 (0.48, 3.67) | −1.23 (−4.46, 2.00) | 0.457 |
| CKD (eGFR<60 ml/min/1.73m2) | Acute (≤6M) |
Intensive | 0.06 (−2.93, 3.05) | −1.97 (−3.49, −0.45) | 2.03 (−1.10, 5.16) | 0.204 |
|
| ||||||
| CKD (eGFR<60 ml/min/1.73m2) | Chronic (>6M) |
Standard | −1.41 (−2.50, −0.32) | −0.60 (−1.13, −0.06) | −0.81 (−2.03, 0.40) | 0.190 |
| CKD (eGFR<60 ml/min/1.73m2) | Chronic (>6M) |
Intensive | −0.82 (−1.91, 0.27) | −0.75 (−1.24, −0.26) | −0.07 (−1.26, 1.12) | 0.908 |
|
| ||||||
| Non-CKD (eGFR≥60 ml/min/1.73 m2) | Acute (≤6M) |
Standard | −0.18 (−3.29, 2.93) | 0.48 (−0.98, 1.94) | −0.66 (−3.77, 2.45) | 0.679 |
| Non-CKD (eGFR≥60 ml/min/1.73 m2) | Acute (≤6M) |
Intensive | −5.44 (−8.27, −2.60) | −3.99 (−5.49, −2.48) | −1.45 (−4.31, 1.42) | 0.322 |
|
| ||||||
| Non-CKD (eGFR≥60 ml/min/1.73 m2) | Chronic (>6M) |
Standard | −1.17 (−2.71, 0.36) | −1.20 (−1.72, −0.69) | 0.03 (−1.59, 1.64) | 0.975 |
| Non-CKD (eGFR≥60 ml/min/1.73 m2) | Chronic (>6M) |
Intensive | −1.83 (−3.18, −0.49) | −1.20 (−1.75, −0.64) | −0.64 (−2.09, 0.81) | 0.388 |
a
For acute time period (≤6 months (M) post-randomization), slopes reflect mean change in eGFR (in ml/min/1.73m2) over 6 months. For chronic time period (>6M post-randomization), slopes reflect mean change in eGFR per one year.
b
Adjusted for baseline eGFR, age, sex, history of cardiovascular disease, proportion of African admixture, and whether or not measurement occurred at a fasting study visit.